KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-cash Items (2018 - 2025)

Adaptive Biotechnologies' Non-cash Items history spans 8 years, with the latest figure at $15.4 million for Q3 2025.

  • For Q3 2025, Non-cash Items rose 1018.41% year-over-year to $15.4 million; the TTM value through Sep 2025 reached $15.4 million, up 1018.41%, while the annual FY2024 figure was $2.2 million, N/A changed from the prior year.
  • Non-cash Items for Q3 2025 was $15.4 million at Adaptive Biotechnologies, down from $29.4 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $109.1 million in Q1 2021 and bottomed at $1.1 million in Q3 2023.
  • The 5-year median for Non-cash Items is $10.2 million (2022), against an average of $27.8 million.
  • The largest annual shift saw Non-cash Items crashed 93.13% in 2022 before it soared 1018.41% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $96.8 million in 2021, then plummeted by 93.13% to $6.7 million in 2022, then plummeted by 83.34% to $1.1 million in 2023, then soared by 94.68% to $2.2 million in 2024, then surged by 612.42% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Non-cash Items are $15.4 million (Q3 2025), $29.4 million (Q2 2025), and $2.2 million (Q4 2024).